SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-049470
Filing Date
2021-09-23
Accepted
2021-09-23 09:00:26
Documents
14
Period of Report
2021-09-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea147815-8k_actinium.htm   iXBRL 8-K 32485
2 PRESS RELEASE DATED SEPTEMBER 23, 2021 (FURNISHED HEREWITH PURSUANT TO ITEM 7.01 ea147815ex99-1_actinium.htm EX-99.1 25420
6 GRAPHIC ex99-1_001.jpg GRAPHIC 38311
  Complete submission text file 0001213900-21-049470.txt   297240

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnm-20210922.xsd EX-101.SCH 3043
4 XBRL LABEL FILE atnm-20210922_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE atnm-20210922_pre.xml EX-101.PRE 22371
7 EXTRACTED XBRL INSTANCE DOCUMENT ea147815-8k_actinium_htm.xml XML 3614
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

IRS No.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36374 | Film No.: 211271173
SIC: 2834 Pharmaceutical Preparations